The leadership team at Corium brings together industry-leading experts in drug
development, manufacturing, and commercialization who are dedicated to
doing more for our partners and patients.
Perry Sternberg, President and Chief Executive Officer
Perry Sternberg, CEO of Corium Inc, delivers a vision of a healthcare company that is patients’ and caregivers’ partner of choice. Based on an ethos of community and compassion, Corium strives to make a difference in the lives of others. As CEO, Perry focuses the company’s efforts on the empowerment of patients, caregivers, and its employees.
According to Perry, every existing and potential relationship relies on the organic building of good communication and trust, not one-sided messaging. Leading a healthcare business means being approachable, treating others with respect, and being open and eager to hear others’ ideas. As Perry says, “Every person has something valuable and important to bring to the table when it comes to improving patient and caregiver outcomes.”
In his 25 years of experience in biotechnology and pharmaceuticals, Perry has overseen the launches of more than 20 products across a wide range of therapeutic areas in diverse markets. Under his leadership, Corium has filed and submitted for FDA approval a prescription treatment for Alzheimer’s disease. The company has also continued its strategic partnerships to bring to market an ADHD treatment and produce contraception and in-demand oral care products. Perry is passionate about, and thrilled by, the future that Corium is building for the people the company seeks to serve.
Perry spends his downtime with his wife, 3 children, and their family dog, and enjoys travel.
Dan Arsulowicz, Vice President, Grand Rapids Operations
Robyn Lynch, Head of Corporate Strategy & Business Planning
John Miller, Chief Financial Officer
John Neeley, Head of Market Access, Supply Chain and Project Management
Terry Ocheltree, Ph.D., R.Ph., Head of Regulatory and Quality Assurance
Dr. Ocheltree was most recently at Certara as Vice President of Regulatory Strategy and CMC, expanding their drug development and regulatory capabilities. Previously, he founded PharmTree Consultants, an independent regulatory consulting firm specializing in chemistry, manufacturing and controls (CMC) regulatory affairs. Prior to PharmTree, he served as Senior Director of Regulatory CMC and Senior Director of Regulatory Policy and Intelligence at AbbVie. While at the FDA, Dr. Ocheltree reviewed and responded to INDs, NDAs, and sNDAs, participated in industry meetings, led multi-functional teams, developed guidances (including transdermal and botanical) and championed the use of Quality by Design (QbD), Process Analytical Technology (PAT), Real Time Release Testing (RTRT) and Product Lifecycle Management. Before his tenure at the FDA, Dr. Ocheltree held various scientific and technical roles at 3M Pharmaceuticals, Cardinal Health and Morton Grove Pharmaceuticals, and worked in both retail and hospital pharmacy, establishing a first-in-class specialty service pharmacy for Greenville Health Corporation. He is also an adjunct professor at the University of Wisconsin and has served in the same role and as pharmacy preceptor for multiple other colleges and universities. He is an active member of numerous trade and professional organizations and has served on PhRMA, EFPIA and IFPMA committees. Dr. Ochetree holds a BA in Interdisciplinary Studies and a BS in Pharmacy from the University of South Carolina and a Ph.D. in Pharmaceutics from the Medical University of South Carolina.
Charles Oh, M.D., Chief Medical Officer
Dr. Oh received his medical degree from the Washington University in St. Louis. He also has an MBA from the University of North Carolina at Chapel Hill and a BS in Biology from the University of Miami (FL).